The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck (NYSE:MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, ...

U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...